copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Soleno Therapeutics – Development and commercialization of novel . . . Soleno is committed to maximizing shareholder value by developing and commercializing innovative therapeutic products with the goal of improving the lives of individuals living with complex, life-threatening rare diseases with unmet medical needs
Products - Soleno Triple Wall Pipe TripleFlo is the triple-wall pipe offered exclusively by Soleno Rigid pipe with smooth interior and exterior walls for drainage applications Composed of three interconnected layers of HDPE, it is designed to offer an exceptional level of rigidity
Investor Relations – Soleno Therapeutics Inc. Corporate Profile Soleno Therapeutics, Inc (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases
ABOUT US - Soleno USA With more than 550 employees across 13 industrial sites, the Group SOLENO is one of the largest manufacturers of HDPE pipes and one of the largest plastic recyclers in Eastern Canada
Soleno Therapeutics, Inc. (SLNO) - Yahoo Finance Find the latest Soleno Therapeutics, Inc (SLNO) stock quote, history, news and other vital information to help you with your stock trading and investing
Welcome to Soleno Therapeutics Medical Affairs Access medical content and resources intended for U S healthcare providers to facilitate the exchange of scientific information and educational resources regarding Soleno medicines and therapeutic areas of interest
Soleno Les solutions et produits offerts par Soleno permettent un accès optimal à la forêt et un drainage efficace afin de préserver et prolonger la durée de vie des chemins forestiers
Our Medicine – Soleno Therapeutics Soleno Therapeutics, Inc (Soleno) is dedicated to the development and commercialization of novel therapeutics for the treatment of rare diseases The company’s lead product, VYKAT™ XR (diazoxide choline) extended-release, is a once-daily oral treatment for hyperphagia in individuals aged 4 and older who have Prader-Willi syndrome (PWS)